-
Signature
-
/s/ Keith Regnante, Attorney-in-Fact
-
Issuer symbol
-
KROS
-
Transactions as of
-
19 Feb 2026
-
Net transactions value
-
-$113,433
-
Form type
-
4
-
Filing time
-
20 Feb 2026, 16:15:17 UTC
Quoteable Key Fact
"Jasbir Seehra filed Form 4 for Keros Therapeutics, Inc. (KROS) on 20 Feb 2026."
Quick Takeaways
- This page summarizes Jasbir Seehra's Form 4 filing for Keros Therapeutics, Inc. (KROS).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 20 Feb 2026, 16:15.
What Changed
- Previous filing in this sequence was filed on 09 Jan 2026.
- Current net transaction value: -$113,433.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Seehra Jasbir |
CHIEF EXECUTIVE OFFICER, Director |
C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON |
/s/ Keith Regnante, Attorney-in-Fact |
20 Feb 2026 |
0001732369 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
KROS |
Common Stock |
Sale |
$113,433 |
-7,015 |
-1.8% |
$16.17 |
385,708 |
19 Feb 2026 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses: